Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Mega Cap Growth ETF (MGK) vs Merck & Co., Inc. (MRK) Price & Performance

Vanguard Mega Cap Growth ETFTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Vanguard Mega Cap Growth ETF vs Merck & Co., Inc. — how do they compare? Vanguard Mega Cap Growth ETF trades at $90.34, while Merck & Co., Inc. trades at $132.37 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals.

MGKMRK
Sector
Broad Market / FactorHealth
52-Week High
$92.06$131.84
52-Week Low
$70.70$77.60
Market Cap
$321.77B
Enterprise Value
$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Mega Cap Growth ETF

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Mega Cap Growth ETF

MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.

Read more on MGK

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK